{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-017557","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2025-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.563605+00:00","generated_at":"2026-05-18T09:42:11.618763+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Mira-55 shows morphine-comparable pain relief in animal model; SKNY acquisition clears SEC review","bullets":["Mira-55, a non-psychoactive marijuana analog, matched morphine's pain relief in a formalin-based rodent model without sedation or inflammation.","DEA previously confirmed Mira-55 is not a controlled substance, removing a key regulatory barrier to clinical development.","SEC completed review of merger proxy for SKNY Pharmaceuticals acquisition with no comments, enabling shareholder vote.","SKNY-1, the target therapy, demonstrated 30% body weight reduction without muscle loss and reversal of nicotine cravings in recent studies.","MIRA advancing Mira-55 toward IND submission for inflammatory pain indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-017557","json":"https://secwatch.observer/filing/0001641172-25-017557.json","markdown":"https://secwatch.observer/filing/0001641172-25-017557.md","text":"https://secwatch.observer/filing/0001641172-25-017557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225017557/0001641172-25-017557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225017557/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:42:11.618763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}